PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biomoda, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biomoda Supports Nebraska Legislation To Screen Veterans for Lung Cancer - Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer
Biomoda Supports Nebraska Legislation To Screen Veterans for Lung Cancer

 

NewswireToday - /newswire/ - Albuquerque, NM, United States, 2010/01/25 - Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“The Nebraska Legislature has taken another step toward saving lives,” said Biomoda President and CEO John Cousins. “Lung cancer is the deadliest cancer killer, primarily because it is too difficult and too expensive to diagnose in its earliest stages when it is most treatable.”

If Legislative Bill 987 is enacted, the Nebraska Department of Veterans’ Affairs would receive $650,000 to contract with the University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases to conduct the screening program based on a non-invasive diagnostic tool developed by Biomoda and currently in clinical trials. Biomoda’s CyPath® diagnostic is for investigational use only pending approval by the U.S. Food and Drug Administration (FDA).

“Veterans of the armed services are at least 25 percent more likely than the general population to be diagnosed with lung cancer. Screening programs like the one proposed by this bill in Nebraska and an earlier one enacted by the New Mexico Legislature help us spotlight one of the most serious health issues facing the men and women who serve in uniform,” Cousins said. “We want to acknowledge Sen. Krist, who is himself a retired Air Force lieutenant colonel, for introducing this bill, and we look forward to working with the Eppley Institute which is internationally renowned for its research on the causes, diagnosis and treatment of cancer.”

If the Nebraska study is funded, volunteers will provide a deep-lung sputum sample to be tested for cancer cells with the CyPath® labeling solution, a porphyrin-based compound that preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. Results will be compared to a computed tomography (CT) scan, currently the standard of care for detection of lung cancer, and sputum Pap stains read by independent cytopathologists.

About Biomoda

Biomoda (biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. Current research and development operations, laboratory functions for both microscopy and assay formulation, and administrative offices are located in Albuquerque, NM.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biomoda, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biomoda Supports Nebraska Legislation To Screen Veterans for Lung Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: John Cousins - Biomoda.com 
505-821-0875 investor[.]biomoda.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biomoda, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biomoda, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)